Acetazolamide
Metastatic Non Small Cell Lung Cancer
Obsidian Therapeutics, Inc.Small moleculePhase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 89/ 100
Competitive context
7 Active assets in the Metastatic Non Small Cell Lung Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Etirinotecan Pegol Joel Neal | Phase 2 | B |
Tedopi Fondazione Ricerca Traslazionale | Phase 2 | CCC |
Lifileucel Iovance Biotherapeutics, Inc. | Phase 2 | CCC |
ADG 106 National University Hospital, Singapore | Phase 1/2 | CC |
Obx-115 Obsidian Therapeutics, Inc. | Phase 1/2 | CC |
C-Til051 AbelZeta Inc. | Phase 1 | CC |
mov19-bbz car t cells University of Pennsylvania | Phase 1 | CC |
Nktr-255 AbelZeta Inc. | Phase 1 | CC |
Same molecule, other indications
Acetazolamide is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →